-
Pembrolizumab (Keytruda®) Approved as First-Line Option for Lung Cancer
Anti-PD-1 checkpoint antibody is the only immunotherapy approved for first-line treatment for lung cancer patients.
-
FDA Approves Another Immunotherapy Option for Patients with Advanced Lung Cancer
Anti-PD-L1 atezolizumab is the second PD-1 pathway drug approved for lung cancer this month.
-
Checkpoint Inhibitors Benefit Lung Cancer Patients in Clinical Trials
Patients with metastatic non-small cell lung cancer could soon have a new first-line immunotherapy treatment option.
-
CICON16: The Future of Cancer Immunotherapy
CICON16 ended by focusing on emerging treatments and technologies in cancer immunotherapy.
-
CICON16: The Power of Combinations
Targeting tumors from multiple angles improves our odds of success.
-
CICON16: Bacteria and Cancer Immunity
New research shows that bacteria within us can influence both the development of cancer and the immune…
-
CICON16: Corrupted by Cancer
Day 2 of CICON16 explored strategies to overcome challenges within the tumor microenvironment.
-
CICON16: Beyond PD-1 and CTLA-4: The New Checkpoints
The latest advances in using new checkpoint drugs to target LAG-3, Nrp1, IL-35R, CD36, and mitochondrial metabolism.
-
CICON16: Cancer Antigens and the Development of Personalized Immunotherapy Approaches
Antigens are the key to effective vaccines and the immune system’s ability to target cancer cells.
